The *Nucleoporin 98* gene (*NUP98*) is a promiscuous gene implicated in chromosomal aberrations in hematopoietic disorders. *NUP98* encodes a 98-kDa protein of the nuclear pore complex that regulates nucleocytoplasmic transport of protein and RNA. Twenty-eight different NUP98 partner genes have been identified across various human hematological malignancies,^[@bib1],\ [@bib2]^ many of which encode for homeodomain (HD) transcription factors and chromatin-modifying factors. We report here two new oncogenic fusions for *NUP98*, involving the homeobox gene *genetic screened homeobox 2 (GSX2,* formerly *Gsh2)* and the putative zinc-finger transcription factor gene *ALL-1 fused gene from chromosome 10* (*AF10)/MLLT10*.

Patient 1 is a 57-year-old woman with a post-myeloproliferative neoplasm M4 acute myeloid leukemia (AML) associated with a t(4;11)(q12;p15) translocation and trisomy 8. Patient 2 is an 83-year-old man who developed an atypical myelodysplastic syndrome resembling chronic myelomonocytic leukemia associated with a t(10;11)(p12;p15) translocation. Molécular cytogenetic techniques demonstrated the *NUP98-GSX2* and *NUP98-AF10* fusions for the t(4;11) and the t(10;11) respectively (not shown). Reverse transcriptase (RT)-PCR using primers located within *NUP98*, *GSX2* and *AF10* exons validated the presence of the *NUP98--GSX2* and *NUP98--AF10* fusion transcripts in patient samples ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). Nucleotide sequencing showed an in-frame fusion of the *NUP98* exon 12 with *GSX2* exon 2, predicting a putative chimeric protein of 59 kDa that joins the Gly-Leu-Phe-Gly (GLFG) repeats of the amino-terminal part of NUP98 at the carboxy (C)-terminal part of GSX2 containing a HD ([Figure 1](#fig1){ref-type="fig"}). Sequence analysis of the *NUP98--AF10* fusion transcript showed an in-frame fusion of *NUP98* exon 11 with *AF10* exon 15, predicting a 1027-amino-acid protein with the NUP98 GLFG repeats fused to the C-terminal part of the AF10 protein including the octapeptide motif-leucine-zipper (OM-LZ) domain and the glutamine-rich (Q-rich) sequence of AF10, but without the nuclear localization signal (NLS) region.

Both *AF10* and *GSX2* genes have been involved in human hematological malignancies*. GSX2* is a brain-specific class II homeobox gene of the Antennapedia family that regulates the development of mouse embryonic telencephalon.^[@bib3]^ It has been associated with acute leukemia through its involvement in the recurrent t(4;12)(q11q12;p13) translocation.^[@bib4]^ AF10 belongs to a family of proteins that includes AF17 and BR140 characterized by the presence of a C-terminal OM-LZ domain. AF10 is considered a putative transcription factor, binding DNA through an AT hook motif and interacting with the SWI/SNF chromatin remodeling complex.^[@bib5]^ Through its OM-LZ domain, AF10 interacts with the histone methyltransferase hDOT1L that methylates the lysine 79 residues of histone H3 (H3K79),^[@bib6],\ [@bib7]^ a mark associated with an open-chromatin configuration. In hematological malignancies, *AF10* is fused to the *mixed lineage leukemia* (*MLL*) gene by the t(10;11)(p12;q23) translocation^[@bib8]^ and to the *clathrin assembly lymphoid myeloid leukemia* (*CALM*) gene by the t(10;11)(p12;q14) translocation.^[@bib9]^

The transformation potential of the two *NUP98* fusions was investigated by transducing murine primary bone marrow (BM) hematopoietic progenitors, defined as lineage-negative cells, by murine stem cell virus (MSCV) retroviral vectors containing different versions of Flag-tagged *NUP98--GSX2* and *NUP98--AF10* sequences as reported.^[@bib10]^ Cells were transduced with MSCV expressing the native *NUP98--GSX2 and NUP98--AF10* fusions, fusions deleted for the conserved functional domains (*NUP98--GSX2-*⊗*HD* and *NUP98--AF10-ΔOM-LZ*) or with the empty MSCV. Transduced cells were seeded in methylcellulose medium for serial plating assays. We observed that *NUP98--GSX2*-transduced progenitors formed numerous colonies after the fourth round of replating, whereas control cells were not replated after the third round ([Figure 2a](#fig2){ref-type="fig"}). Cytological analysis of the colonies showed that cells expressing *NUP98--GSX2* exhibit a blast morphology, whereas empty MSCV-transduced progenitors formed monocytic and mast cell colonies (not shown). In contrast, *NUP98--GSX2-*⊗*HD*-transduced progenitors showed no proliferative advantage and were not able to form colonies after the second replating, thus illustrating that the transforming effect of the *NUP98--GSX2* fusion requires the G*SX*2 HD. Immunofluorescence analysis showed a marked nuclear presence for the NUP98--GSX2 protein, whereas NUP98--GSX2-⊗HD was located both in the nucleus and in the cytosol with a diffuse staining pattern ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). These data demonstrated that the *NUP98--GSX2* fusion encodes a nuclear protein with a GSX2 HD-dependent oncogenic capacity. Progenitors transduced with *NUP98--AF10* were able to produce a significantly increased number of colonies up to the third round of plating, contrary to the *NUP98--AF10-ΔOM-LZ*-transduced cells, which did not generate a significant number after the second round of plating ([Figure 2a](#fig2){ref-type="fig"}). Thus, expression of *NUP98--AF10* is sufficient to induce a proliferative advantage in progenitor BM cells and this proliferative effect depends on the integrity of the OM-LZ region. CALM--AF10 (as well as some MLL fusions) participates in gene deregulation by virtue of hDOT1L recruitment at target gene loci, in particular for certain *HOXA* genes. As its transforming potential is linked to the integrity of the OM-LZ domain, we hypothesized that the oncogenic capacity of NUP98--AF10 is linked to *HOXA* gene deregulation by a process similar to that involved in *MLL--AF10* and *CALM--AF10* fusions. We performed quantitative RT-PCR to measure the levels of the *HOXA5*, *HOXA7*, *HOXA9*, *HOXA10* transcripts and that of the HOX cofactor *MEIS1* transcript in patient 2\'s (*NUP98--AF10* fusion) BM cells ([Figure 2b](#fig2){ref-type="fig"}) (no material was available for patient 1). Expression analyses were performed in parallel in samples from patients with *AML1-ETO*-positive leukemia (*n*=2) as a negative control for *HOXA* expression, and in samples from patients with *MLL--AF10* (*n*=1)- and *NUP98--HOXA9* (*n*=2)-positive leukemia as positive controls. In patient 2\'s BM cells, we observed an elevated expression of *HOXA5*, *HOXA7*, *HOXA9* and *MEIS1* as in leukemic cells with *MLL--AF10* and *NUP98--HOXA9* fusions. *HOXA10* was specifically overexpressed in the *MLL--AF10* sample. No *HOXA* cluster gene expression was observed in *AML1-ETO* BM cells. In murine models, *NUP98* fusions are often associated with upregulation of *HOXA* cluster and *MEIS1* genes in blast cells.^[@bib11],\ [@bib12],\ [@bib13]^ Thus, *NUP98--AF10*-transduced BM cells were engrafted into sublethally irradiated mice. Mice transplanted with cells transduced with empty (*n*=10) or *NUP98--AF10* MSCV vectors (*n*=5) remained free of hematological disease up to 12 months after transplantation (not shown), contrary to those receiving cells transduced with the *NUP98--HMGB3* fusion.^[@bib10]^ Altogether, our results indicate that contrary to the *MLL--AF10* and *CALM--AF10* fusions,^[@bib14],\ [@bib15]^ *NUP98--AF10* has only weak oncogenic power. This may be explained by the lack of an exclusively nuclear localization for NUP98--AF10 due to the absence of the NLS of AF10 in the chimeric protein.

In conclusion, the identification of *AF10* and *GSX2* as new *NUP98* partner genes in hematological malignancies strengthens the predominance of homeobox and chromatin-modifier genes as *NUP98* partners and the deregulation of *HOXA* cluster genes as an oncogenic mechanism in several *NUP98*-associated leukemia.

This works was supported by grants from The Ligue Nationale Contre le Cancer (LNCC). GS was a recipient from the Fondation pour la Recherche Médicale (FRM).

[Supplementary Information](#sup1){ref-type="supplementary-material"} accompanies this paper on Blood Cancer Journal website (http://www.nature.com/bcj)

The authors declare no conflict of interest.

Supplementary Material {#sup1}
======================

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

![Schematic representation of the native or chimeric AF10 and GSX2 and NUP98 proteins. RNP-BD, ribonucleoparticle binding domain; PHD, plant homeodomain; Q-rich, glutamine-rich region.](bcj201320f1){#fig1}

![(**a**) Serial colony-plating assay of bone marrow progenitors transduced by wild-type, NUP98, NUP98--GSX2, NUP98--AF10 or empty vector. The average colony numbers±s.d. values are shown for three independent experiments. (**b**) Quantitative RT-PCR analyses of the *HOXA5*, *HOXA7*, *HOXA9*, *HOXA10* and *MEIS1* gene expression from RNA of various human AML samples carrying the following fusion genes: AML1-ETO (*n*=2), MLL--AF10 (*n*=1), NUP98--HOXA9 (*n*=2) and NUP98--AF10 (*n*=1). Expression was normalized with respect to *ABL* expression.](bcj201320f2){#fig2}
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